Results 41 to 50 of about 54,917 (299)

Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry

Cardiovascular Diabetology, 2022
Background The inflammatory response occurring in acute myocardial infarction (AMI) has been proposed as a potential pharmacological target. Sodium-glucose co-transporter 2 inhibitors (SGLT2-I) currently receive intense clinical interest in patients with
Pasquale Paolisso, Luca Bergamaschi, Gaetano Santulli, Emanuele Gallinoro, Arturo Cesaro, Felice Gragnano, Celestino Sardu, Niya Mileva, Alberto Foà, Matteo Armillotta, Angelo Sansonetti, Sara Amicone, Andrea Impellizzeri, Gianni Casella, Ciro Mauro, Dobrin Vassilev, Raffaele Marfella, Paolo Calabrò, Emanuele Barbato, Carmine Pizzi   +19 more
doaj   +1 more source

Sympathetic Activation Promotes Sodium Glucose Co-Transporter-1 Protein Expression in Rodent Skeletal Muscle

Biomedicines
The hyperactivation of the sympathetic nervous system (SNS) is linked to obesity, hypertension, and type 2 diabetes, which are characterized by elevated norepinephrine (NE) levels.
Jennifer R. Matthews, Lakshini Y. Herat, Markus P. Schlaich, Vance B. Matthews   +3 more
doaj   +1 more source

SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria [PDF]

Importance  Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce chronic kidney disease (CKD) progression in individuals with type 2 diabetes, CKD, or heart failure.
Wanner, Christoph, Cherney, David Z. I., Perkovic, Vlado, Zannad, Faiez, Jardine, Meg J., McGuire, Darren K., Solomon, Scott D., Fletcher, Robert A., Sabatine, Marc S., Staplin, Natalie, Docherty, Kieran F., Inzucchi, Silvio E., Vaduganathan, Muthiah, Butler, Javed, Bhatt, Deepak L., Neal, Bruce, McCausland, Finnian R., Herrington, William G., Anker, Stefan D., McMurray, John J. V., Neuen, Brendon L., Heerspink, Hiddo J. L., Haynes, Richard, Patel, Siddharth M., Packer, Milton, Mahaffey, Kenneth W., Sardell, Rebecca J., Wheeler, David C.   +27 more
core   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

A review on the medicinal chemistry of sodium glucose co-transporter 2 inhibitors (SGLT2-I): Update from 2010 to present

European Journal of Medicinal Chemistry Reports, 2022
Diabetes mellitus (DM) is one of the leading causes of death by World Health Organization in 2019 and is considered a significant cause of other diseases including heart attack, stroke, kidney failure, blindness, and lower limb amputation. Sodium glucose
Jonali Ramani, Harshil Shah, Vivek K. Vyas, Manmohan Sharma   +3 more
doaj   +1 more source

Efficacy and safety of empagliflozin for treating neutropenia and neutrophil dysfunction in paediatric patients with glycogen storage disease type Ib: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims Glycogen storage disease type Ib (GSD‐Ib) is a rare genetic disorder causing neutropenia and neutrophil dysfunction in children. G‐CSF has been the primary treatment, but emerging data support the potential of empagliflozin, an SGLT2 inhibitor, as a promising investigational option.
Elizabeth Iwasyk, Ryan Jin, Fabio Tuzzolino, Giusy Ranucci, Donatella Madonia, Alessio Provenzani   +5 more
wiley   +1 more source

Recent Developments in Diabetes Management: Exploring Receptors, Pathways, and Compounds

BIO Integration
Diabetes mellitus (DM) is a widespread metabolic disorder with profound effects on vital organs. Often referred to as a “systemic” or “multi-organ” disorder due to the impact on key organs, such as the kidneys, pancreas, eyes, and heart, DM is ...
Pallavi Pandey, Vikash Jakhmola, Supriyo Saha, Anand Gaurav   +3 more
doaj   +1 more source

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism

Frontiers in Pharmacology, 2022
Sodium-glucose cotransporter 2 (SGLT2) inhibitors exert hypoglycemic and diuretic effects by inhibiting the absorption of sodium and glucose from the proximal tubule.
Jun Tang, Jun Tang, Lifang Ye, Lifang Ye, Qiqi Yan, Qiqi Yan, Xin Zhang, Xin Zhang, Lihong Wang, Lihong Wang   +9 more
doaj   +1 more source

BDNF Levels and Cognitive Function in Patients with Type 2 Diabetes Treated with SGLT2 Inhibitors [PDF]

Objective: As cognitive impairment becoming more widely recognized as a complication of type 2 diabetes mellitus (T2DM), it is discussed in the literature that antihyperglycemic treatment may also improve cognitive functions.
Esra ÇALIŞICI, Betül SÜMBÜL ŞEKERCİ, Abdüsselam ŞEKERCİ, Şeymanur DEMİRHAN, Sekerci, Abdusselam, Calisici, Esra, Demirhan, Seymanur, Sümbül Şekerci, Betül, Çalışıcı, Esra   +8 more
core   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source